• CEL-SCI launched a global Phase 3 confirmatory registration study for Multikine in newly diagnosed, resectable, locally advanced head and neck cancer.
• Trial targets about 212 patients with low or zero PD-L1 expression and no clinical lymph node involvement, based on a high-responder subgroup from its prior Phase 3 study.
• Study design aims for about 97% power to detect a 0.34 hazard ratio on overall survival.
• In the prior Phase 3 subgroup, 5-year overall survival was 73% with Multikine versus 45% with standard of care alone.
• Company plans to use early pre-surgical tumor response endpoints to support potential accelerated or conditional approvals while overall survival follow-up continues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260713392922) on July 13, 2026, and is solely responsible for the information contained therein.